Bexorg Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
48
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$23M
- Investors
-
6
Bexorg General Information
Description
Developer of human-brain drug perfusion technology designed to advance the development of treatments for neurological diseases. The company combines whole-human-brain perfusion technology with AI-driven molecular analysis to evaluate drug exposure, target engagement, and therapeutic responses in human brain tissue, enabling researchers and drug developers to conduct detailed studies of neurological conditions for more precise predictive CNS drug development.
Contact Information
Website
www.bexorg.comCorporate Office
- 290 Congress Avenue
- New Haven, CT 06519
- United States
Corporate Office
- 290 Congress Avenue
- New Haven, CT 06519
- United States
Bexorg Timeline
Bexorg Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series A) | 23-Sep-2025 | $23M | Completed | Generating Revenue | ||
| 1. Early Stage VC (Series A) | 01-Oct-2023 | Completed | Generating Revenue |
Bexorg Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Series A-2 | ||||||||
| Series A-1 | 1,772,394 | $0.000010 | $6.02 | $6.02 | 1x | $6.02 | 9.01% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Bexorg Patents
Bexorg Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260354373-A1 | Perfusion and metabolic restoration of organs | Pending | 08-May-2025 | ||
| WO-2026236029-A1 | Perfusion and metabolic restoration of organs | Pending | 08-May-2025 | ||
| WO-2026156072-A1 | Method of isolating extracellular hemoglobin protein from worms | Pending | 15-Jan-2025 | ||
| US-20260200972-A1 | Perfusion and metabolic restoration of organs | Pending | 15-Jan-2025 | ||
| EP-4837195-A1 | Graph-based machine learning for artificial brain perfusion experiments | Pending | 03-Jan-2025 |
Bexorg Signals
Bexorg Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Amplify Partners | Venture Capital | Minority | ||
| Connecticut Innovations | Venture Capital | Minority | ||
| E1 Ventures | Venture Capital | Minority | ||
| Starbloom Capital | Venture Capital | Minority | ||
| BluePrint (Asset Management) | VC-Backed Company | Minority |
Bexorg FAQs
-
When was Bexorg founded?
Bexorg was founded in 2021.
-
Where is Bexorg headquartered?
Bexorg is headquartered in New Haven, CT.
-
What is the size of Bexorg?
Bexorg has 48 total employees.
-
What industry is Bexorg in?
Bexorg’s primary industry is Discovery Tools (Healthcare).
-
Is Bexorg a private or public company?
Bexorg is a Private company.
-
What is the current valuation of Bexorg?
The current valuation of Bexorg is .
-
What is Bexorg’s current revenue?
The current revenue for Bexorg is .
-
How much funding has Bexorg raised over time?
Bexorg has raised $42.5M.
-
Who are Bexorg’s investors?
Amplify Partners, Connecticut Innovations, E1 Ventures, Starbloom Capital, and BluePrint (Asset Management) are 5 of 6 investors who have invested in Bexorg.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process